Answers are grounded in this paper and cite their sources.
Recent patents disclose complementary strategies to optimize psychedelic-assisted therapy. Novel psilocin prodrugs improve pharmacokinetics and stability, while digital systems enable cognitive state monitoring during treatment. Parallel advances in combining neuroplastogen drugs with transcranial electrical stimulation highlight a model-driven approach to enhance and personalize neural plasticity. Together, these innovations converge on a precision framework for treating neuropsychiatric disorders.
No takes yet. Share an insight, caveat, or question.
Renner et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: